Viewing Study NCT05355168


Ignite Creation Date: 2025-12-24 @ 5:58 PM
Ignite Modification Date: 2026-01-05 @ 5:30 PM
Study NCT ID: NCT05355168
Status: COMPLETED
Last Update Posted: 2024-12-31
First Post: 2022-04-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Sponsor: Anhui Provincial Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module